Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers

Huang, Zhiyu; Zhang, Maoqing; Li, Jiayue; Lou, Chenghua

doi:10.1016/j.biopha.2023.114756

Cited by 6 publications

(8 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the rapid development of biomedicine, the role of lncRNAs in various physiological and pathological processes of cancer has been gradually clarified, which can even be explored as promising prognostic biomarkers and therapeutic targets for malignancies ( 33 , 34 ). As a novel lncRNA, MAFG-AS1 is recognized as a vital oncogene since it has intimate terms with unfavorable clinicopathologic parameters and poor prognosis in cancer patients ( 12 ). Mechanistically, the underlying cell biological functions behind its role in carcinomas are extremely complex.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, mounting evidence suggested that lcnRNAs were highly associated with prognosis in various malignancies and may be novel targets for cancer detection and therapy ( 9 , 10 ). For example, the MAF transcription factor G antisense RNA 1 (MAFG-AS1), a novel lncRNA with a transcript size of 1914bp, is located on chromosome 17q25.3 ( 11 , 12 ). Clinical studies had demonstrated that elevated expression of MAFG-AS1 could accelerate the progression of diverse kinds of cancers, including breast cancer, bladder cancer, hepatocellular carcinoma, lung cancer, gastric cancer, colorectal cancer, glioblastoma, ovarian cancer, prostate cancer, pancreatic cancer, and esophageal squamous cell cancer (ESCC) ( 12 ).…”

Section: Introductionmentioning

confidence: 99%

“…For example, the MAF transcription factor G antisense RNA 1 (MAFG-AS1), a novel lncRNA with a transcript size of 1914bp, is located on chromosome 17q25.3 ( 11 , 12 ). Clinical studies had demonstrated that elevated expression of MAFG-AS1 could accelerate the progression of diverse kinds of cancers, including breast cancer, bladder cancer, hepatocellular carcinoma, lung cancer, gastric cancer, colorectal cancer, glioblastoma, ovarian cancer, prostate cancer, pancreatic cancer, and esophageal squamous cell cancer (ESCC) ( 12 ). Basically, overexpression of MAFG-AS1 is closely connected to higher histological grade, lymph node metastasis (LNM), larger tumor size, and shorter overall survival (OS) in many human cancers ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

“…Basically, overexpression of MAFG-AS1 is closely connected to higher histological grade, lymph node metastasis (LNM), larger tumor size, and shorter overall survival (OS) in many human cancers ( 13 ). Simultaneously, accumulating experiments indicated that MAFG-AS1 participated in various biological effects, such as promoting migration, proliferation, and epithelial-mesenchymal transition (EMT), along with inhibiting apoptosis of carcinoma ( 12 ). Collectively, MAFG-AS1 appeals to a wide range of clinicians and may serve as a potential predictor of carcinoma prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Lin,

Liu,

Lin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMAF transcription factor G antisense RNA 1 (MAFG-AS1), a novel long non-coding RNA discovered recently, was proved to be useful in predicting malignancy prognosis. Nevertheless, its association with cancer prognosis has been inconsistent. Therefore, this meta-analysis aimed to explore the clinicopathological and prognostic significance of MAFG-AS1 in diverse carcinomas.MethodsStudies focused on MAFG-AS1 expression as a prognostic role in cancers were thoroughly searched in six electronic databases. The value of MAFG-AS1 in malignancies was assessed by hazard ratios (HRs) or odds ratios (ORs). Additionally, the GEPIA database was utilized to further strengthen our conclusion.ResultsA total of 15 studies involving 1187 cases and nine types of cancers were recruited into this meta-analysis. High MAFG-AS1 expression was significantly related to advanced tumor stage (OR = 0.52, 95%CI [0.39, 0.69], P < 0.00001), earlier lymph node metastasis (OR = 3.62, 95%CI [2.19, 5.99], P < 0.00001), worse tumor differentiation (OR = 0.64, 95%CI [0.43, 0.95], P = 0.03), and poor overall survival (HR = 1.94, 95%CI [1.72, 2.19], P < 0.00001). No significant heterogeneity and publication bias was detected across studies. Meanwhile, MAFG-AS1 was significantly elevated in ten kinds of cancers based on the validation of the GEPIA database.ConclusionThe results of this meta-analysis indicated that high MAFG-AS1 expression is dramatically correlated with unfavorable prognosis in cancers. MAFG-AS1 may be served as a promising biomarker for malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Lin,

Liu,

Lin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…With the development of molecular biology and genomics, lncRNAs have emerged as promising biomarkers for cancer and individual lncRNAs have different characteristics in different cancers ( 12 ). Certain lncRNAs are involved in important biological processes in cancer development through the regulation of target genes, including DNA methylation, histone modification and chromatin remodeling ( 13 ), and have considerable roles in the processes of proliferation, migration and invasion in a variety of tumors, which are closely related to treatment strategies and prognoses of these patients. For instance, lncRNA hypoxia-inducible factor 1α-antisense 2 (AS2) is an oncogenic KRAS-inducible lncRNA and its high expression may promote lung cancer cell proliferation and tumor metastasis ( 14 ).…”

Section: Overview Of Lncrnasmentioning

confidence: 99%

Long non‑coding RNAs, lipid metabolism and cancer (Review)

Zhang,

Hou,

Cao

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

Cancer has emerged as the most common cause of death in China. The change in lipid metabolism has been confirmed to have a role in several tumor types, such as esophageal, gastric, colorectal and liver cancer. Cancer cells use lipid metabolism for energy and then rapidly proliferate, invade and migrate. The main pathway by which cancer cell lipid metabolism influences cancer progression is increased fatty acid synthesis. Long non-coding (lnc)RNAs are important ncRNAs that were indicated to have significant roles in the development of human tumors. They are considered potential tumor biomarkers. Increased lipid synthesis or uptake due to deregulation of lncRNAs contributes to rapid tumor growth. In the present review, current studies on the relationship between lncRNAs, lipid metabolism and the occurrence and development of tumors were collated and summarized, and their mechanism of action was discussed. The review is expected to provide a theoretical basis for tumor treatment and prognosis evaluation based on the effective regulation of lncRNAs and lipid metabolism.

show abstract

m⁶A modification of lncRNA PHKA1‐AS1 enhances Actinin Alpha 4 stability and promotes non‐small cell lung cancer metastasis

Guo,

Zhang,

Zhou

et al. 2024

MedComm

View full text Add to dashboard Cite

Cancer is a disease with molecular heterogeneity that is closely related to gene mutations and epigenetic changes. The principal histological subtype of lung cancer is non‐small cell lung cancer (NSCLC). Long noncoding RNA (lncRNA) is a kind of RNA that is without protein coding function, playing a critical role in the progression of cancer. In this research, the regulatory mechanisms of lncRNA phosphorylase kinase regulatory subunit alpha 1 antisense RNA 1 (PHKA1‐AS1) in the progression of NSCLC were explored. The increased level of N6‐methyladenosine (m6A) modification in NSCLC caused the high expression of PHKA1‐AS1. Subsequently, high‐expressed PHKA1‐AS1 significantly facilitated the proliferation and metastasis of NSCLC cells, and these effects could be reversed upon the inhibition of PHKA1‐AS1 expression, both in vivo and in vitro. Additionally, the target protein of PHKA1‐AS1 was actinin alpha 4 (ACTN4), which is known as an oncogene. Herein, PHKA1‐AS1 could enhance the protein stability of ACTN4 by inhibiting its ubiquitination degradation process, thus exerting the function of ACTN4 in promoting the progress of NSCLC. In conclusion, this research provided a theoretical basis for further exploring the potential mechanism of NSCLC metastasis and searching novel biomarkers related to the pathogenesis and progression of NSCLC.

show abstract

Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers

Cited by 6 publications

References 55 publications

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Long non‑coding RNAs, lipid metabolism and cancer (Review)

m⁶A modification of lncRNA PHKA1‐AS1 enhances Actinin Alpha 4 stability and promotes non‐small cell lung cancer metastasis

Contact Info

Product

Resources

About

Long non-coding RNA MAFG-AS1: A promising therapeutic target for human cancers

Cited by 6 publications

References 55 publications

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Correlation between long non-coding RNA MAFG-AS1 and cancer prognosis: a meta-analysis

Long non‑coding RNAs, lipid metabolism and cancer (Review)

m6A modification of lncRNA PHKA1‐AS1 enhances Actinin Alpha 4 stability and promotes non‐small cell lung cancer metastasis

Contact Info

Product

Resources

About

m⁶A modification of lncRNA PHKA1‐AS1 enhances Actinin Alpha 4 stability and promotes non‐small cell lung cancer metastasis